Prognostic factors in breast cancer

Seminars in Oncology

Volumn 19, Issue 3, 1992, Pages 244-253

  Elledge, Richard M ^a   McGuire, William L ^a   Osborne, C Kent ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; STEROID RECEPTOR;

BREAST CANCER; CANCER INCIDENCE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VOLUME;

BREAST NEOPLASMS; CATHEPSIN D; FEMALE; HUMAN; ONCOGENE PROTEINS, VIRAL; PLOIDIES; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, STEROID; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026769158     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Cancer statistics, 1991
2. Five year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with and without radiation in the treatment of breast cancer
3. Ten year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with and without radiation
4. Patterns of relapse and survival following radical mastectomy
5. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node negative breast cancer who have estrogen-receptor-negative tumors
6. A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
7. Efficacy of adjuvant chemotherapy in high risk node-negative breast cancer
8. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer
9. Systemic therapy in patients with node-negative breast cancer
10. Breast cancer therapy exercising all our options
11. Adjuvant therapy of node-negative breast cancer
12. Cancer of the breast: size of neoplasm and prognosis
13. Prognostic factors in primary breast cancer
14. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons
15. Relationship of tumor size, lymph node status, and survival in 24,740 breast cancer cases
16. Long term followup of breast cancer patients: the 30 year report
17. 0) breast carcinoma: a study of 644 patients with median followup of 18 years
18. Tumor cellularity estrogen receptors and prognosis in breast cancer
19. The value of estrogen and progesterone receptors in the treatment of breast cancer
20. Progesterone receptors as a prognostic factor in stage II breast cancer
21. Estrogen receptor protein of breast cancer cells as a predictor of recurrence
22. Progesterone and estrogen receptors as prognostic variables in breast cancer
23. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term followup
24. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative breast cancer
25. Prognosis in breast cancer
26. How to use prognostic factors in axillary node-negative breast cancer patients
27. Relative worth of estrogen or progesterone receptors and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients
28. Indicators of prognosis in node-negative breast cancer
29. Tumor nuclear grade, estrogen receptor, and progesterone receptor as an indicator of outcome following adjuvant therapy for breast cancer
30. Heterogenicity of tumors
31. Inter- and intraobserver variability in the histopathologic diagnosis of medullary carcinomas of the breast and its prognostic implications
32. Interobserver reproducibility of histopathological features in Stage II breast cancer
33. Histologic grading and prognosis in breast cancer
34. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis
35. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson(SBR)
36. Nuclear characteristics as indicators of prognosis in node negative breast cancer patients
37. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP)
38. Histologic malignancy grading of invasive ductal breast cancer
39. Medullary breast carcinoma
40. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma
41. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry
42. Tumour DNA ploidy as an independent prognostic factor in breast cancer
43. Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphologic factors
44. 0 carcinoma of the breast
45. Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients
46. The relationship of flow cytometry to clinical and biologic characteristics in women with node-negative primary breast cancer
47. Prediction of recurrence and therapy response in the node negative breast cancer patient by DNA flow cytometry an Eastern Cooperative Oncology (ECOG) Intergroup Study
48. Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry
49. Prediction of relapse or survival in patients with node negative breast cancer by DNA flow cytometry
50. A new S-phase model predicts recurrence for aneuploid as well as diploid node-negative breast cancer
51. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction
52. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
53. The neu gene: an erbB homologous gene distinct from and unlinked to the gene encoding athe EGF receptor
54. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2
55. c-erbB-2 expression in benign and malignant breast tissue
56. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
57. An evaluation of immune-reactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer
58. Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
59. Neu-protein overexpression in breast cancer
60. HER-2/neu amplification predicts poor survival in node-positive breast cancer
61. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
62. HER-2/neu oncogene protein and prognosis in breast cancer
63. Amplification of the c-erbB-2 oncogene and prognosis in breast cancer
64. An immunohistochemical evaluation of c-erbB-2 expression in human breast cancer
65. c-erbB-2 mRNA expression in human breast tumours: Comparison with c-erbB-2 DNA amplification and correlation with prognosis
66. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease
67. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer
68. HER-2/neu expression identified a group of node-negative breast cancer patients at high risk for recurrence
69. Estrogeninduced lysosomal proteases secreted by breast cancer cells a role in carcinogenesis
70. Processing and estrogen regulation of the 52-kilodalton protein inside MCF-7 breast cancer cell
71. Structure, function, regulation and clinical significance of the 52 kd pro-cathepsin D secreted by breast cancer cells
72. Increased secretion, altered processing and glyosylation of procathepsin D in human mammary cancer cells
73. Autocrine growth stimulation by the MCF-7 breast cancer cells by the estrogen-regulated 52 kd protein
74. Association between high concentration of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer
75. Cathepsin D: an independent prognostic factor for metastasis of breast cancer
76. Cathepsin D and prognosis in breast cancer
77. Epidermal growth factor
78. Epidermal growth factor stimulation on human breast cancer cells in culture
79. A native 170,000 dalton epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles
80. Protein tyrosine kinases
81. Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences
82. Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissue: relationship to estrogen receptor and lymphatic invasion
83. Prognostic value of epidermal growth factor receptor in node-positive breast cancer
84. Epidermal growth factor receptor in human breast cancer: correlation with steroid receptors and axillary node involvement
85. Expression of epidermal growth factor receptor in breast carcinoma
86. Epidermal growth factor receptor status as a predictor of early recurrence of and death from breast cancer
87. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer
88. Estrogeninducible heat shock protein hsp27 predicts recurrence in node negative breast cancer
89. Clinical significance of heat-shock/stress-response proteins in breast cancer
90. Stress response protein (SRP27) determination in primary human breast carcinomas: Clinical, histologic, and prognostic correlations
91. Sequence of pS2 mRNA induced by estrogen in the human breast cancer cell line
92. Prediction of relapse and survival in breast cancer patients by pS2 protein status
93. pS2 expression and response to hormonal therapy in patients with advanced breast cancer
94. Evidence for a novel gene associated with low tumor metastatic potential
95. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis
96. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential
97. Independent prognostic value of laminin receptor expression in breast cancer survival
98. Haptoglobin-related protein (Hpr) epitopes in breast cancer as predictor of recurrence of the disease
99. Prognostic value of receptors for insulin-like growth factor I, somatostatin and epidermal growth factor in human breast cancer
100. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
101. Systematic treatment of early breast cancer by hormonal cytotoxic or immune therapy
102. Systematic treatment of early breast cancer by hormonal cytotoxic or immune therapy